Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Single-Blind, Randomized, Placebo-Controlled Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (FASCINATE-1)

Next Previous
Trial Profile

A Phase 2, Multi-Center, Single-Blind, Randomized, Placebo-Controlled Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (FASCINATE-1)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denifanstat (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms FASCINATE-1
  • Sponsors Sagimet Biosciences

Most Recent Events

  • 08 Nov 2022 Results exploring baseline metabolomic biomarkers to predict response to denifanstat presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
  • 08 Nov 2022 Results determining the impact of denifanstat-mediated DNLinhibition on metabolic effects in NASH patients presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
  • 31 Oct 2022 According to a Sagimet Biosciences media release, data will be presented at AASLDs The Liver Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top